A Phase 2 interventional study of VK2735 and Placebo in Weight Loss, sponsored by Viking Therapeutics, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.
Sponsored by Viking Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,479 studies in Overweight with a site in United States — 273 open to participants now, 400 under way, 69 of them phase 3. Overweight · United States.
Among the 1,479 studies in Overweight with a site in United States, this one is the 443rd largest by enrollment of the 1,365 interventional ones that give a count, is one of 93 that started in 2023, is one of 147 in phase 2, and was the 1,027th registered.
3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.
Browse Overweight studies →273 of the 1,479 studies in Overweight with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–70
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
University of California, Los Angeles · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,479 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 148 · Phase 2 177 · Phase 3 126 · Phase 4 31
First in 1983; this study’s year is marked. 93 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 78 across 3,132 interventional studies indexed under Overweight.
Median enrollment 85 across the 1,365 interventional studies, 126 across the 112 observational. Of the 1,017 that completed or were terminated, 247 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
380 of 1,479 have an industry lead sponsor. The 10 most frequent:
Viking Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Viking Therapeutics, Inc. has 1 study filed under Overweight — fewer than ten, so there is no comparison to draw.
157 of the studies in Overweight with a site in United States that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07298915Phase 3University of VirginiaThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | 2026-12 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
Add all 157 to your calendar (.ics) → With an account.
Among the 1,479 studies in Overweight with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.
VK2735 or matched placebo will be administered once weekly.
3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.
This study's enrollment of 176 is above the median of 78 across 3,132 interventional studies indexed under Overweight.
Browse Overweight studies →Viking Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Compared within Overweight, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Weight Loss. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Biological: Placebo
VK2735 is a peptide GLP-1 and GIP dual agonist
Biological: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist
Biological: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist
Biological: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist
Biological: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist
Placebo comparator
Percent (relative) change from baseline to Week 13 in body weight
To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Time frame: 13 weeks
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13
To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Time frame: 13 weeks
Incidence of treatment-emergent adverse events (TEAEs), TESAEs, AESI
To evaluate the safety and tolerability of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Time frame: 13 weeks
Ran from Aug 2023 to primary completion in Feb 2024, 5 months.
Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's 5 months is below that.
Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VK2735